- #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorBristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey…Endpoints · 1mo ago↗ source
- Pfizer, Innovent strike $10B cancer drug deal<figure><div><img src="https://imgproxy.divecdn.com/MR_ueNISGsuP2HU9tITuSVUs34rcuaidMyQcZYbmwDU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8yWDJIQ0U1LmpwZw==.webp"/></div></f…BioPharma Dive · 1mo ago↗ source
- David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at PhlowLongtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...